Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Gam-COVID-Vac (Sputnik V) in Volunteers Over 60
NCT04587219Phase 2
Key facts
- Status
- Unknown
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Countries
- 1
- Modality
- Viral Vector Vaccines
- Drugs
- Gam-COVID-Vac
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 2, open-label, single-arm trial of Gam-COVID-Vac in coronavirus disease 2019 (COVID-19). Primary endpoints: Changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days and Number of Participants With Adverse Events at 180 days. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Gam COVID Vac Vaccine
Prime-boost immunization with Gam-COVID-Vac
03
Who it enrols
Volunteers over 60 years old without history of COVID-19, severe allergies, or recent vaccinations.
04
Endpoints
Primary
Changing of antibody levels against the SARS-CoV-2 glycoprotein S
Number of Participants With Adverse Events
Secondary
Changing of virus neutralizing antibody titer
Changing of antigen-specific cellular immunity level
Beyond the preview
Go deeper on NCT04587219.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587219.